240 related articles for article (PubMed ID: 11416714)
21. HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients.
Falloon J; Ait-Khaled M; Thomas DA; Brosgart CL; Eron JJ; Feinberg J; Flanigan TP; Hammer SM; Kraus PW; Murphy R; Torres R; Masur H;
AIDS; 2002 Feb; 16(3):387-96. PubMed ID: 11834950
[TBL] [Abstract][Full Text] [Related]
22. A prospective comparison of the two main indications of efavirenz in 2001 highly active antiretroviral therapy (HAART) regimens: first-line versus salvage use.
Manfredi R; Calza L; Chiodo F
J Antimicrob Chemother; 2002 May; 49(5):723-9. PubMed ID: 12003964
[TBL] [Abstract][Full Text] [Related]
23. Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.
Ochoa de Echagüen A; Arnedo M; Xercavins M; Martinez E; Rosón B; Ribera E; Domingo P; González A; Riera M; Llibre JM; Gatell JM; Dalmau D;
AIDS; 2005 Sep; 19(13):1385-91. PubMed ID: 16103769
[TBL] [Abstract][Full Text] [Related]
24. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386
[TBL] [Abstract][Full Text] [Related]
25. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
[TBL] [Abstract][Full Text] [Related]
26. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.
Matthews GV; Sabin CA; Mandalia S; Lampe F; Phillips AN; Nelson MR; Bower M; Johnson MA; Gazzard BG
AIDS; 2002 Jan; 16(1):53-61. PubMed ID: 11741163
[TBL] [Abstract][Full Text] [Related]
27. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M
AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586
[TBL] [Abstract][Full Text] [Related]
28. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C.
Grossman Z; Istomin V; Averbuch D; Lorber M; Risenberg K; Levi I; Chowers M; Burke M; Bar Yaacov N; Schapiro JM;
AIDS; 2004 Apr; 18(6):909-15. PubMed ID: 15060438
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
Sterrantino G; Borghi V; Callegaro AP; Bruzzone B; Saladini F; Maggiolo F; Maffongelli G; Andreoni M; De Gennaro M; Gianotti N; Bagnarelli P; Vergori A; Antinori A; Zazzi M; Zaccarelli M;
Int J Antimicrob Agents; 2019 Apr; 53(4):515-519. PubMed ID: 30769200
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
[TBL] [Abstract][Full Text] [Related]
31. Efavirenz: resistance and cross-resistance.
Clotet B
Int J Clin Pract Suppl; 1999 Jun; 103():21-5. PubMed ID: 10622039
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
[TBL] [Abstract][Full Text] [Related]
33. Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy.
Quiros-Roldan E; Airoldi M; Moretti F; Fausti C; Pan A; Casari S; Torti C; Castelli F; Carosi G
J Clin Lab Anal; 2002; 16(2):76-8. PubMed ID: 11948795
[TBL] [Abstract][Full Text] [Related]
34. Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
Marcelin AG; Descamps D; Tamalet C; Cottalorda J; Izopet J; Delaugerre C; Morand-Joubert L; Trabaud MA; Bettinger D; Rogez S; Ruffault A; Henquell C; Signori-Schmuck A; Bouvier-Alias M; Vallet S; Masquelier B; Flandre P; Calvez V;
Antivir Ther; 2012; 17(1):119-23. PubMed ID: 22267476
[TBL] [Abstract][Full Text] [Related]
35. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
36. Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients.
Langmann P; Weissbrich B; Desch S; Väth T; Schirmer D; Zilly M; Klinker H
Eur J Med Res; 2002 Jul; 7(7):309-14. PubMed ID: 12176680
[TBL] [Abstract][Full Text] [Related]
37. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
38. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
[TBL] [Abstract][Full Text] [Related]
39. The use of efavirenz as a part of late rescue antiretroviral treatment.
Manfredi R; Rizzo E; Calza L; Chiodo F
HIV Clin Trials; 2001; 2(5):413-20. PubMed ID: 11673816
[TBL] [Abstract][Full Text] [Related]
40. Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Geretti AM; Fox Z; Johnson JA; Booth C; Lipscomb J; Stuyver LJ; Tachedjian G; Baxter J; Touloumi G; Lehmann C; Owen A; Phillips A;
PLoS One; 2013; 8(7):e69266. PubMed ID: 23874928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
